Synthesis and Characterization of Celecoxib Derivatives as Possible Anti-Inflammatory, Analgesic, Antioxidant, Anticancer and Anti-HCV Agents
作者:Ş. Küçükgüzel、İnci Coşkun、Sevil Aydın、Göknur Aktay、Şule Gürsoy、Özge Çevik、Özlem Özakpınar、Derya Özsavcı、Azize Şener、Neerja Kaushik-Basu、Amartya Basu、Tanaji Talele
DOI:10.3390/molecules18033595
日期:——
A series of novel N-(3-substituted aryl/alkyl-4-oxo-1,3-thiazolidin-2-ylidene)-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamides 2a–e were synthesized by the addition of ethyl a-bromoacetate and anhydrous sodium acetate in dry ethanol to N-(substituted aryl/alkylcarbamothioyl)-4-[5-(4-methylphenyl)-3-(trifluoro-methyl)-1H-pyrazol-1-yl]benzene sulfonamides 1a–e, which were synthesized by the reaction of alkyl/aryl isothiocyanates with celecoxib. The structures of the isolated products were determined by spectral methods and their anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV NS5B RNA-dependent RNA polymerase (RdRp) activities evaluated. The compounds were also tested for gastric toxicity and selected compound 1a was screened for its anticancer activity against 60 human tumor cell lines. These investigations revealed that compound 1a exhibited anti-inflammatory and analgesic activities and further did not cause tissue damage in liver, kidney, colon and brain compared to untreated controls or celecoxib. Compounds 1c and 1d displayed modest inhibition of HCV NS5B RdRp activity. In conclusion, N-(ethylcarbamothioyl)-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (1a) may have the potential to be developed into a therapeutic agent.
一系列新型 N-(3-取代芳基/烷基-4-氧代-1、2-亚基)-4-[5-(4-甲基苯基)-3-(三氟甲基)-1H-吡唑-1-基]苯磺酰胺 2a-e 的合成。溴乙酸乙酯和无水乙酸钠在干燥乙醇中与 N-(取代的芳基/烷基氨基甲硫酰基)-4-[5-(4-甲基苯基)-3-(三氟甲基)-1H-吡唑-1-基]苯磺酰胺 1a-e 反应合成、由烷基/芳基异硫氰酸酯与塞来昔布反应合成。通过光谱方法确定了分离产物的结构,并评估了它们的抗炎、镇痛、抗氧化、抗癌和抗 HCV NS5B RNA 依赖性 RNA 聚合酶(RdRp)活性。此外,还测试了化合物的胃毒性,并筛选出化合物 1a 对 60 种人类肿瘤细胞株的抗癌活性。这些研究表明,与未经处理的对照组或塞来昔布相比,化合物 1a 具有抗炎和镇痛活性,而且不会对肝、肾、结肠和大脑造成组织损伤。化合物 1c 和 1d 对 HCV NS5B RdRp 的活性有一定的抑制作用。总之,N-(乙基氨基甲硫基)-4-[5-(4-甲基苯基)-3-(三氟甲基)-1H-吡唑-1-基]苯磺酰胺(1a)可能具有开发成治疗药物的潜力。